Promising new data are presented for nivolumab plus ipilimumab and the single tremelimumab regular interval durvalumab regimen in Asian patients and those with impaired liver function
Early results from a phase III trial support 30-minutes infusions of immunotherapy with some advantages for patients
Positive data presented from the LEAP-012 study for intermediate-stage disease, but it is still unclear how these will influence clinical practice
Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced disease
Novel agents, a rethinking of accepted treatment concepts and new roles for older treatment modalities are now driving liver cancer management
Innovative approaches are investigated to predict cancer development in patients with cirrhosis and detect early recurrence after resection
Research is moving forward to adapt clinical practice to a new wave of early-onset cases of cancer in the digestive tract
Data from the IMbrave050 study show benefits of atezolizumab plus bevacizumab in terms of disease recurrence, but long-term data are needed
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.